If you are wondering whether DexCom stock still offers value after a choppy few years, this article walks through what the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 ...

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you ...

DexCom develops and markets continuous glucose monitoring (CGM) systems, a type of device that continuously tracks blood sugar levels. The technology isn't exactly new anymore, and it has enjoyed ...

Compare the best Samsung Watch CGM apps and Wear OS tools for blood sugar readings, including Dexcom G6, Gluroo, and xDrip+.

CGM technology, which allows diabetes patients to track their blood glucose levels efficiently throughout the day, has been linked with better outcomes. As clinical evidence has piled up, third-party ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...